Nabriva Therapeutics plc (NASDAQ:NBRV) shares traded down 5.1% on Thursday . The stock traded as low as $1.12 and last traded at $1.12. 5,499 shares traded hands during trading, a decline of 99% from the average session volume of 974,000 shares. The stock had previously closed at $1.18.
A number of equities analysts have recently commented on NBRV shares. Zacks Investment Research upgraded shares of Nabriva Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price objective for the company in a research report on Wednesday. HC Wainwright reiterated a “neutral” rating on shares of Nabriva Therapeutics in a research report on Wednesday, May 26th.
The company has a current ratio of 4.29, a quick ratio of 3.80 and a debt-to-equity ratio of 0.09. The company has a fifty day simple moving average of $1.34.
A number of institutional investors have recently bought and sold shares of NBRV. FMR LLC lifted its stake in Nabriva Therapeutics by 77.0% in the first quarter. FMR LLC now owns 3,261,500 shares of the biotechnology company’s stock worth $7,958,000 after purchasing an additional 1,418,800 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Nabriva Therapeutics by 1,025.0% in the fourth quarter. Renaissance Technologies LLC now owns 342,360 shares of the biotechnology company’s stock worth $829,000 after purchasing an additional 311,927 shares during the last quarter. Squarepoint Ops LLC bought a new stake in Nabriva Therapeutics in the first quarter worth $260,000. Jane Street Group LLC bought a new stake in Nabriva Therapeutics in the first quarter worth $78,000. Finally, Virtu Financial LLC bought a new stake in Nabriva Therapeutics in the fourth quarter worth $53,000. 0.86% of the stock is owned by institutional investors and hedge funds.
Nabriva Therapeutics Company Profile (NASDAQ:NBRV)
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; and SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI).
Recommended Story: Backdoor Roth IRA Conversion and Strategy
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.